Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

262
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

245
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
245
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

65
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
65
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.6K
T Cell Types and Functions01:24

T Cell Types and Functions

1.6K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unravelling Fibromyalgia in Psoriatic Arthritis.

Rheumatology and therapy·2026
Same author

Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease.

RMD open·2025
Same author

Isolated Lower Limb Vasculitis Following SARS-CoV-2 Infection: A Case Report.

Cureus·2024
Same author

Time to flare in giant cell arteritis and polymyalgia rheumatica: analysis from a single-centre Australian practice.

Internal medicine journal·2024
Same author

The prevalence and impact of polypharmacy in rheumatology.

Rheumatology (Oxford, England)·2023
Same author

Emerging injectable therapies for osteoarthritis.

Expert opinion on emerging drugs·2022

Related Experiment Video

Updated: Oct 23, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

454

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.

Kate E Findeisen1, Julia Sewell1, Andrew J K Ostor2,3

  • 1The Alfred Hospital, Melbourne, Victoria, Australia.

Biologics : Targets & Therapy
|August 20, 2021
PubMed
Summary

Biological disease modifying anti-rheumatic drugs (bDMARDs) have transformed rheumatoid arthritis (RA) treatment. This review covers their classes, real-world use, and integration into RA guidelines.

Keywords:
bDMARDsbiological therapiesrheumatoid arthritis

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

525
A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

8.5K

Related Experiment Videos

Last Updated: Oct 23, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

454
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

525
A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

8.5K

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with significant patient and societal costs.
  • Biological disease-modifying anti-rheumatic drugs (bDMARDs) represent a major advancement in RA therapy.

Purpose of the Study:

  • To review the current landscape of bDMARDs for rheumatoid arthritis.
  • To discuss the different classes, efficacy, and safety profiles of available bDMARDs.
  • To examine the real-world application and guideline integration of bDMARDs in RA management.

Main Methods:

  • Literature review of current bDMARDs used in rheumatoid arthritis treatment.
  • Analysis of molecular targets, efficacy, and safety data for each bDMARD class.
  • Discussion of clinical guidelines and real-world evidence for bDMARD utilization.

Main Results:

  • Five distinct classes of bDMARDs are currently available for RA treatment.
  • Each bDMARD class targets different molecules, leading to varied efficacy and safety outcomes.
  • Real-world data informs the practical application of bDMARDs within established RA treatment protocols.

Conclusions:

  • bDMARDs have significantly impacted rheumatoid arthritis management.
  • Understanding the nuances of different bDMARD classes is crucial for optimizing patient care.
  • The integration of bDMARDs into treatment guidelines reflects their established role in managing RA.